Shin Nippon Biomedical Laboratories Ltd.

Kainan, Japan

Shin Nippon Biomedical Laboratories Ltd.

Kainan, Japan
SEARCH FILTERS
Time filter
Source Type

Patent
Shin Nippon Biomedical Laboratories Ltd. and Wave Life Sciences | Date: 2016-11-23

Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having immunity-inducing activity and an immunity-inducing activator. Solution The present invention relates to an adjuvant which comprises oligonucleotides which comprise two to four sequences each represented by 5-X_(1)CpG X_(2)-3 and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3 end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3 end and 5 end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an immunity-inducible activator comprising the adjuvant.


Patent
Shin Nippon Biomedical Laboratories Ltd. and Wave Life Sciences | Date: 2016-11-23

To provide a chiral nucleic acid adjuvant and anti-allergic agent having anti-allergic effect. An adjuvant which comprises oligonucleotides which comprise two to four CpG motifs each represented by 5-X_(1)CpGX_(2)-3 and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3 end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3 end and 5 end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an adjuvant comprising the oligonucleotide represented by the sequence number 67. The present invention relates to an anti-allergic agent comprising these adjuvant.


Patent
Shin Nippon Biomedical Laboratories Ltd. and Wave Life Sciences | Date: 2016-11-23

The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having anti-tumor activity; and an anti-tumor agent. The present invention relates to an adjuvant for anti-tumor agent, wherein the adjuvant comprises oligonucleotides which comprise two to four CpG motif each represented by 5-X_(1)CpGX_(2)-3 and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3 end side of at least two CpG motifs is connected by phosphorothioate linkage,wherein each nucleic acid at 3 end and 5 end of the oligonucleotide is S type nucleic acid connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an anti-tumor agent containing its adjuvant.


Patent
Shin Nippon Biomedical Laboratories Ltd. and Wave Life Sciences | Date: 2015-01-14

Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having immunity-inducing activity and an immunity-inducing activator. Solution The present invention relates to an adjuvant which comprises oligonucleotides which comprise two to four sequences each represented by 5-X_(1)CpG X_(2)-3 and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3 end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3 end and 5 end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an immunity-inducible activator comprising the adjuvant.


Patent
Shin Nippon Biomedical Laboratories Ltd. and Wave Life Sciences | Date: 2015-01-14

An adjuvant which comprises oligonucleotides which comprise two to four CpG motifs each represented by 5-X_(1)CpGX_(2)-3 and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3 end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3 end and 5 end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an adjuvant comprising the oligonucleotide represented by the sequence number 67. The present invention relates to an anti-allergic agent comprising these adjuvant.


Patent
Shin Nippon Biomedical Laboratories Ltd. and Wave Life Sciences | Date: 2015-01-14

Summary Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having anti-tumor activity; and an anti-tumor agent. Solution The present invention relates to an adjuvant for anti-tumor agent, wherein the adjuvant comprises oligonucleotides which comprise two to four CpG motif each represented by 5-X_(1)CpGX_(2)-3 and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3 end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acid at 3 end and 5 end of the oligonucleotide is S type nucleic acid connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an anti-tumor agent containing its adjuvant.


[Problem] The present invention addresses the problem of providing a novel compound. The present invention also addresses the problem of providing an OCT3 detection agent or an OCT3 activity inhibitor, which comprises the novel compound. [Solution] A compound represented by formula (A), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.R^(1)-R^(2)-R^(3)-R^(4)(A)


Patent
Shin Nippon Biomedical Laboratories Ltd. | Date: 2015-04-01

The present invention reduces or eliminates injuries such as those to the base of the limbs of a primate in a restrainer caused by friction with vertical bars in the grid of a barrier that is movable in a front-back direction, by reducing the friction when using the barrier to restrain the primate. A restrainer (10) for primates has: a storage body (20) having two side surfaces, a top surface, and a bottom surface; a rear surface door (50) which can open and close the rear surface side of the storage body (20); and a barrier (30) that is formed so as to be movable inside the storage body (20) in a front-back direction, and that is formed so as to be fixable at a desired position inside the storage body (20). Protective tubing (33) is rotatably inserted onto vertical bar members (31) of the barrier (30) at locations on the vertical bar members (31) where the base parts of the limbs of a primate would make contact when the limbs of the primate are extended in the frontal direction and restrained.


Patent
Shin Nippon Biomedical Laboratories Ltd. and Wave Life Sciences | Date: 2015-05-20

The purpose of the present invention is to provide: a stereo isomer of a novel CpG oligonucleotide, which has excellent stability; and a CpG oligonucleotide which has a capability of producing interferon- (IFN). The present invention relates to an oligonucleotide which contains two to four sequences each represented by the formula 5-X_(1)X_(2)CpGX_(3)X_(4)-3 (formula (I)) and has a length of 14 to 32 nucleotides. In formula (I), CpG represents a non-methylated CpG residue having a phosphate skeleton modification, X_(1)X_(2) represents any one of AA, AT, GA and GT, and X_(3)X_(4) represents any one of TT, AT, AC and CG. The oligonucleotide has at least one phosphate skeleton modification at an S-form stereoisomer located at a site other than the CpG.


[Problem] To provide an OCT3 activity inhibitor having a different basic skeleton than that of conventional OCT3 activity inhibitors. [Solution] This inhibitor of organic cation transporter 3 (OCT3) contains, as an active component, an imidazo[1,2-a]pyridine derivative, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof

Loading Shin Nippon Biomedical Laboratories Ltd. collaborators
Loading Shin Nippon Biomedical Laboratories Ltd. collaborators